Novartis Loses Bid to Block Generic Entresto, J&J Cuts Neurology Programs
Key Insights
A U.S. judge ruled that the FDA can approve generic versions of Novartis' heart failure (search) drug Entresto, which generated over $6 billion in revenue last year.
Novartis plans to appeal the decision, but the launch of the generic version still faces other legal challenges.
Johnson & Johnson is discontinuing several programs, primarily in neurology and psychiatry, as well as reducing its involvement in the infectious diseases market.
Novartis has been unsuccessful in its attempt to prevent the FDA from approving generic versions of its blockbuster heart failure (search) drug, Entresto. A U.S. District Judge in Washington, D.C., ruled that the FDA did not exceed its authority in approving MSN Pharmaceutical's generic version, despite Novartis's claims of label differences.
Legal Challenges and Market Impact
Despite the court's decision, the launch of the generic Entresto faces further legal hurdles. Entresto, a key product for Novartis, generated over $6 billion in revenue last year. The company has stated its intention to appeal the ruling, setting the stage for a continued legal battle that could significantly impact the market for heart failure (search) treatments.
J&J Cuts Pipeline Assets
In other news, Johnson & Johnson is scaling back its research and development efforts in neurology and psychiatry. The company is discontinuing several programs in these areas, as well as reducing its presence in the infectious diseases market. The decision reflects a strategic shift in J&J's pipeline priorities.
Kidney Transplants Between HIV-Positive Individuals
A recent study published in the New England Journal of Medicine offers encouraging results for individuals with HIV (search) awaiting organ transplants. The study found that kidney transplants between HIV-positive donors and recipients are safe and effective. Researchers examined 198 kidney transplants across the U.S. and observed similar outcomes whether the donated organ came from a person with or without HIV. This development could potentially shorten the wait times for organs for all patients, regardless of HIV status, by expanding the donor pool.